Seahorse Bioscience

Seahorse Bioscience, now operating under Agilent Technologies after its acquisition, specializes in instruments and tools for cell analysis, particularly focusing on real-time metabolic measurements.

Reviewed by 7wData
Share Email

On this page

Profile

They provide instruments and tools for real-time analysis of cell metabolism and health.

Seahorse Bioscience, now operating under Agilent Technologies after its acquisition, specializes in instruments and tools for cell analysis, particularly focusing on real-time metabolic measurements. Founded as an independent entity, Seahorse was known for its Seahorse XF platform, which measures cellular metabolism in real-time, a critical tool for cancer biology, cardiovascular research, and drug discovery. The acquisition by Agilent in 2015 integrated Seahorse's technology into Agilent's broader life sciences and diagnostics portfolio, enhancing its capabilities in cell analysis.

Today, the Seahorse XF platform remains a cornerstone product, widely used in academic research, pharmaceutical development, and biotech. Agilent's financial reports indicate steady growth in its cell analysis segment, though specific revenue figures for Seahorse products are not separately disclosed. The platform's ability to provide real-time, functional data on live cells has made it indispensable in fields like immunology and developmental biology. Recent SEC filings show Agilent's continued investment in this segment, with R&D expenses allocated to advancing 3D cell model systems and automated imaging solutions.

Track Seahorse Bioscience and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Academic research institutions
  • Pharmaceutical companies
  • Biotechnology firms
  • Clinical diagnostics labs
  • Government research agencies

Strengths and what to watch

Strengths

  • Seahorse XF platform is a market leader in real-time cell metabolism analysis
  • Integration with Agilent's broader life sciences portfolio enhances product reach
  • Strong adoption in high-growth research areas like cancer biology and immunology

Watch for

  • Dependence on Agilent's broader corporate strategy and R&D priorities
  • Competition from newer, more automated cell analysis technologies
  • Potential consolidation in the life sciences tools market affecting pricing and innovation

Key Information

Founded
2001
Headquarters
Billerica, Massachusetts

Frequently Asked Questions

What is Seahorse Bioscience?

Seahorse Bioscience specializes in instruments for real-time cell metabolism analysis. Known for its Seahorse XF platform, it measures cellular metabolism in live cells. Acquired by Agilent Technologies in 2015, it supports research in cancer biology, immunology, and drug discovery.

What is the Seahorse XF platform?

The Seahorse XF platform is a leading tool for real-time analysis of cell metabolism. It provides functional data on live cells, aiding research in cancer biology, cardiovascular studies, and drug discovery. Widely used in academic, pharmaceutical, and biotech research.

How does Seahorse Bioscience fit into Agilent Technologies?

Seahorse Bioscience was acquired by Agilent Technologies in 2015. Its Seahorse XF platform integrates into Agilent’s life sciences portfolio, enhancing cell analysis capabilities. Agilent continues to invest in advancing technologies like 3D cell models and automated imaging.

What industries use Seahorse Bioscience products?

Seahorse Bioscience products are used by academic research institutions, pharmaceutical companies, biotechnology firms, clinical diagnostics labs, and government research agencies. Its Seahorse XF platform is essential for metabolic studies in cancer biology, immunology, and drug development.

What are the applications of Seahorse Bioscience technology?

Seahorse Bioscience technology is applied in cancer biology, cardiovascular research, drug discovery, immunology, and developmental biology. Its real-time cell metabolism analysis provides critical insights into cellular health and function, supporting advancements in these fields.

What challenges does Seahorse Bioscience face?

Seahorse Bioscience faces challenges like dependence on Agilent’s corporate strategy, competition from newer automated technologies, and potential market consolidation. Despite these, its Seahorse XF platform remains a market leader in real-time cell metabolism analysis.

Sources

  1. www.seahorsebio.com — Product portfolio and applications
  2. www.sec.gov — Agilent's acquisition of Seahorse and financial context
  3. www.sec.gov — Historical financial and operational data
  4. www.sec.gov — Post-acquisition integration and performance